| Publications | PubMed=25939062; DOI=10.1038/nm.3855
Grasso C.S., Tang Y.-J., Truffaux N., Berlow N.E., Liu L.-N., Debily M.-A., Quist M.J., Davis L.E., Huang E.C., Woo P.J., Ponnuswami A., Chen S., Johung T.B., Sun W.-C., Kogiso M., Du Y.-C., Qi L., Huang Y.-L., Hutt-Cabezas M., Warren K.E., Le Dret L., Meltzer P.S., Mao H., Quezado M., van Vuurden D.G., Abraham J., Fouladi M., Svalina M.N., Wang N., Hawkins C., Nazarian J., Alonso M.M., Raabe E.H., Hulleman E., Spellman P.T., Li X.-N., Keller C., Pal R., Grill J., Monje M.
Functionally defined therapeutic targets in diffuse intrinsic pontine glioma.
Nat. Med. 21:555-559(2015) PubMed=26115193; DOI=10.1097/NEN.0000000000000216
Taylor I.C., Hutt-Cabezas M., Brandt W.D., Kambhampati M., Nazarian J., Chang H.T., Warren K.E., Eberhart C.G., Raabe E.H.
Disrupting NOTCH slows diffuse intrinsic pontine glioma growth, enhances radiation sensitivity, and shows combinatorial efficacy with bromodomain inhibition.
J. Neuropathol. Exp. Neurol. 74:778-790(2015) PubMed=28823557; DOI=10.1016/j.cell.2017.07.016
Qin E.Y., Cooper D.D., Abbott K.L., Lennon J., Nagaraja S., Mackay A., Jones C., Vogel H., Jackson P.K., Monje M.
Neural precursor-derived pleiotrophin mediates subventricular zone invasion by glioma.
Cell 170:845-859.e19(2017) PubMed=31439867; DOI=10.1038/s41467-019-11732-6
Fons N.R., Sundaram R.K., Breuer G.A., Peng S., McLean R.L., Kalathil A.N., Schmidt M.S., Carvalho D.M., Mackay A., Jones C., Carcaboso A.M., Nazarian J., Berens M.E., Brenner C., Bindra R.S.
PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma.
Nat. Commun. 10:3790.1-3790.10(2019) PubMed=33319914; DOI=10.1093/gigascience/giaa136
Sanders L.M., Cheney A., Seninge L., van den Bout A., Chen M., Beale H.C., Kephart E.T., Pfeil J., Learned K., Lyle A.G., Bjork I., Haussler D., Salama S.R., Vaske O.M.
Identification of a differentiation stall in epithelial mesenchymal transition in histone H3-mutant diffuse midline glioma.
GigaScience 9:giaa136.1-giaa136.14(2020) PubMed=34215733; DOI=10.1038/s41467-021-24168-8
He C., Xu K., Zhu X.-Y., Dunphy P.S., Gudenas B., Lin W.-W., Twarog N., Hover L.D., Kwon C.-H., Kasper L.H., Zhang J.-Y., Li X.-Y., Dalton J., Jonchere B., Mercer K.S., Currier D.G., Caufield W., Wang Y.-Z., Xie J., Broniscer A., Wetmore C., Upadhyaya S.A., Qaddoumi I., Klimo P., Boop F., Gajjar A., Zhang J.-H., Orr B.A., Robinson G.W., Monje M., Freeman B.B. III, Roussel M.F., Northcott P.A., Chen T.-S., Rankovic Z., Wu G., Chiang J., Tinkle C.L., Shelat A.A., Baker S.J.
Patient-derived models recapitulate heterogeneity of molecular signatures and drug response in pediatric high-grade glioma.
Nat. Commun. 12:4089.1-4089.17(2021) PubMed=34732238; DOI=10.1186/s40478-021-01270-y
Xu C., Liu H., Pirozzi C.J., Chen L.H., Greer P.K., Diplas B.H., Zhang L.-W., Waitkus M.S., He Y.-P., Yan H.
TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist.
Acta Neuropathol. Commun. 9:178.1-178.12(2021) |
|---|